RSPH ETF Analysis: SP500 Equal Weight Health | NYSE

Health | NYSE, USA | Market Cap: 908m USD | 12M Return: 28% | US46137V3327 | Charts, Fundamentals & Technical Analysis

Pharmaceuticals, Biotechnology, Medical Equipment, Health Services
Total Rating 70
Safety 72
Buy Signal 0.12
Health
Category Rotation: -0.6
TER: 0.40%
AUM: 908M
Avg Turnover: 4.76M
Risk 3d forecast
Volatility15.4%
VaR 5th Pctl2.69%
VaR vs Median-3.13%
Reward TTM
Sharpe Ratio1.33
Rel. Str. IBD75.4
Rel. Str. Peer Group59.4
Character TTM
Beta0.369
Beta Downside0.335
Hurst Exponent0.456
Drawdowns 3y
Max DD17.13%
CAGR/Max DD0.63
CAGR/Mean DD2.20

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +1.4% 21
Feb -2.0% 21
Mar -0.9% 5
Apr -0.2% 10
May +0.4% 27
Jun +1.2% 19
Jul +3.0% 22
Aug -0.4% 23
Sep -1.9% 30
Oct -1.1% 11
Nov +4.8% 55
Dec -0.4% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RSPH SP500 Equal Weight Health

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a passively managed fund that seeks to track an underlying index by investing at least 90% of its total assets in the indexs component securities. The index itself is built from all companies within the S&P 500 Index that are classified under the health care sector according to the Global Industry Classification Standard (GICS), a sector taxonomy jointly maintained by S&P Dow Jones Indices and MSCI.

Unlike market capitalization-weighted approaches, the funds equal weight methodology assigns each constituent a roughly identical portfolio weight at each rebalance, giving smaller health care companies the same influence on performance as the largest sector names. The GICS health care sector broadly spans four industry groups: pharmaceuticals, biotechnology & life sciences, health care equipment & services, and health care providers, though the funds holdings are restricted to those firms also included in the S&P 500.

Headlines to Watch Out For
  • Drug pricing reforms pressure pharma margins across equal-weight holdings
  • FDA approval pipeline drives biotech valuations in portfolio
  • Interest rate cuts lift small-cap biotech weighting impact
What is the price of RSPH shares?

As of September 22, 2026, the stock is trading at USD 36.84 with a total of 61,573 shares traded. Over the past week, the price has changed by +0.85%, over one month by -2.32%, over three months by +17.68% and over the past year by +27.96%.

Current recommended Stop Loss: 36.20 (which is 1.7% or 1.4 ATR below the current price).

Is RSPH a buy, sell or hold?

SP500 Equal Weight Health has no consensus analysts rating.